Patent: 10,653,773

Summary for Patent: 10,653,773

Title:	Peanut formulations and uses thereof
Abstract:	The present application relates to compositions for oral immunotherapy of peanut allergies. Further, the present application relates to methods for the preparation of the compositions for immunotherapy, and their use in immunotherapy.
Inventor(s):	Walser; Bryan (Menlo Park, CA), Raff; Howard V. (Mill Valley, CA)
Assignee:	Aimmune Therapeutics, Inc. (Brisbane, CA)
Application Number:	16/111,102
Patent Claims:	see list of patent claims

United States Patent 10,653,773 (Ara h 1/Ara h 2/Ara h 6 HPLC QC for peanut-allergy oral products): claim-by-claim scope, critical validity exposures, and the US patent landscape

What does US Patent 10,653,773 claim in peanut allergy manufacturing?

Answer: US 10,653,773 claims a method of making a peanut-allergy oral pharmaceutical composition where QC release/qualification includes assaying peanut flour by HPLC to quantify Ara h 1, Ara h 2, and Ara h 6, comparing results to a reference standard, and using the pass/fail outcome to decide the lot is suitable; then formulating for oral administration (including optional extraction, filtration, protein content measurement, ratio analysis, and capsule/diluent/glidant/lubricant steps).

Independent claim structure and core limitations

Claim 1 (representative independent claim):

1. Assay peanut flour in quality control:

• quantify Ara h 1, Ara h 2, Ara h 6 by HPLC
• compare concentrations to reference standard concentrations
• identify composition as suitable for peanut allergy treatment based on the comparison

2. Formulate the suitable peanut flour for oral administration.

Claim 13 is a parallel “lot-based” version:

• assay and qualify a peanut flour lot
• then formulate peanut flour from the qualified lot.

Claim set coverage summary (what is and is not claimed)

The claim set is tightly focused on (i) target antigens (Ara h 1, Ara h 2, Ara h 6) and (ii) QC analytical method logic (HPLC quantification + reference comparison + suitability decision), followed by (iii) oral formulation/making steps. It does not claim:

• treatment protocols (dose escalation, schedules, immunologic mechanisms)
• clinical efficacy readouts
• crosslinked/modified proteins as such
• specific excipient compositions in a way that would be product-formulation dominant (it only gives mixing categories: diluent/glidant/lubricant and capsule filling)

How broad are the claims versus “quality control” realities?

Answer: The claims are broad at the level of method concept (QC assay + comparison + suitability + formulation), but narrow in required analytical identity (must quantify Ara h 1, Ara h 2, Ara h 6) and in required assay modality (HPLC; with dependent claims specifying RP-HPLC/SEC-HPLC and column types).

Critical interpretation points for infringement mapping

1. “Suitability” decision is a required step.
   The method requires identifying the composition (or lot) as suitable based on comparison to reference standards. A generic manufacturer using HPLC data but not making that suitability decision “based on” comparison to a reference standard could argue design-around, but most regulated QC release processes do make pass/fail decisions against defined specs.

2. Ara h 1/Ara h 2/Ara h 6 are all required.
   Using only Ara h 1 and Ara h 2, or using ELISA panels, or using immunoassays that don’t quantify by HPLC would fall outside the literal wording.

3. HPLC is required.
   Mass spectrometry methods that are not “HPLC” are an argument surface. But many LC-MS workflows are still “HPLC” in broad lay terms; legal construction will matter, especially if the patent defines HPLC behavior or component separation approach.

4. The claims read as “making” steps, not “testing-only” claims.
   Even though the QC logic dominates the assay portion, the claim requires the QC step be part of the “method of making a pharmaceutical composition.” That tends to capture full manufacturing lines where QC release is linked to downstream formulation.

What does each claim add (scope ladder) and where are the weak spots?

Answer: Claims 2–5 (chromatography mode/column), 6–9 (standards and protein accounting), 10–12 (ratio and sample prep), and 25–28 (capsule/excipient categories) add specific optional constraints. The weak points are primarily enablement/definition of reference standards, written description, and whether the claim logic is too general for how reference standards/specs are set in practice.

Claim-by-claim breakdown

Core: Claims 1 and 13

• Claim 1: assays composition by HPLC for Ara h 1/2/6, compares to reference, identifies suitable, then formulates.
• Claim 13: assays peanut flour lot for Ara h 1/2/6, compares to reference, qualifies lot, then formulates.

Practical consequence: a generic or second-source supplier could avoid if the QC release is done with different analytes, different separation technology, or without the “suitability identification based on comparison” step tied to formulation. But in regulated manufacturing, QC release decisions are usually explicit.

Chromatography mode: Claims 2–5, 14–17

• Claims 2,14: HPLC is RP-HPLC
• Claims 3,15: RP-HPLC uses C4 column
• Claims 4,16: RP-HPLC uses C18 column
• Claims 5,17: HPLC is SEC-HPLC

Reading: These are dependent constraints. Infringement of claims 3/4 requires the specific column modes; infringement of claim 5 requires SEC.

Standards and total protein accounting: Claims 6–9, 18–21

• Claims 6,18: use BSA standard to determine Ara h concentrations
• Claims 7,19: determine total protein content
• Claims 8,20: total protein via BSA reference standard or Lowry method
• Claims 9,21: peak areas of Ara h1/2/6 compared to total protein area attributable to protein in chromatogram

Risk surface: “BSA standard to determine concentrations of Ara h 1/2/6” is analytically plausible but can be attacked on written description or enablement if the patent does not provide enough detail to reproduce valid quantification across different Ara h proteins using BSA as the calibrant.

Ratio and sample preparation: Claims 10–12, 22–24

• Claim 10/22: determine Ara h 2 to Ara h 6 ratio
• Claims 11/23: extract proteins from composition (liquid extraction) before HPLC
• Claims 12/24: filter extracted liquid before HPLC

Design-around: using a different sample prep (e.g., direct analysis without extraction, or filterless approach) may avoid dependent claims 11–12/23–24 while still potentially implicating claim 1/13 if those extraction/filter steps are not required for independent coverage.

Capsule and excipient categories: Claims 25–28, 27–28

• Claims 25/27: fill into a capsule
• Claims 26/28: formulate by mixing with a diluent, glidant, or lubricant

Limitation: these dependent claims are commercially relevant because many peanut flour oral products can be capsule-filled or tablet-like. But the patent does not limit to specific excipient names, so non-capsule oral dosage forms could be used to avoid dependent capsule claims, while still risking infringement of claims 1/13 if QC + oral formulation still occur.

How could US 10,653,773 be invalidated or narrowed in litigation?

Answer: The most credible attack points are: (i) whether the claimed subject matter is novel over prior peanut-allergy manufacturing/QC assay disclosures, (ii) whether the use of BSA as a calibrant and the “suitable based on comparison” framework is supported and reproducible for Ara h targets, and (iii) whether the claims are overly broad in functional language relative to the provided embodiments.

Novelty and obviousness attack angles

1. Prior art QC assay combinations for peanut allergen quantification If prior disclosures teach assaying peanut flour lots for Ara h 1/2/6 (or closely related allergens) using LC/HPLC with reference standards, the incremental novelty may be weak.

2. Reference standard pass/fail paradigm “Comparing to a reference standard and identifying as suitable” reads like an industry routine. Unless the patent ties the comparison to particular spec thresholds or provides an integrated QC decision framework unique to peanut flour for oral immunotherapy, obviousness exposure is real.

3. Calibration approach using BSA If prior art uses protein standards or Ara h-specific standards for quantifying Ara h proteins, then using BSA as a universal calibrant could be either:

   • an obvious substitute (KSR-style rationale), or
   • a non-obvious detail if the patent demonstrates validated equivalence and provides enough method detail.

Claim construction vulnerability

• “HPLC comprises use of a C4/C18 column”: construction will matter. Many methods use C18 predominantly; if the patent’s dependent claims are treated strictly, they become narrow but also harder to attack since they’re specific.
• “Identifying … suitable for treatment of peanut allergy”: tying “treatment” to a QC decision could be construed as requiring a decision point that is causally linked to therapeutic intent. Manufacturers can argue their QC decision is regulatory release for a composition intended for peanut allergy treatment, which still aligns with the claim’s phrasing.

What is the practical patent estate around 10,653,773 (US landscape)?

Answer: Based on the claim content provided, the patent sits in the category of manufacturing/QC and specifications patents rather than clinical method patents. That typically means:

• enforcement is strongest against manufacturers and contract manufacturers producing qualifying lots using the claimed QC logic
• enforcement is weaker against distributors or clinical sites that do not perform QC assay-to-suitability decisions

Where this claim set usually fits relative to other peanut-allergy IP

In peanut oral immunotherapy (OIT) portfolios, adjacent US patents commonly cover:

• composition forms (powder/capsules/tablets), excipient blends
• extraction, purification, or protein modification processes
• analytic QC methods (allergen quantification, stability indicators, moisture/water activity, particle size)
• clinical method-of-use regimens (dose escalation, maintenance dosing)

US 10,653,773 overlaps most strongly with QC/analytics and manufacturing release workflow patents. It is less likely to overlap with immunologic mechanism patents unless those mechanism patents include manufacturing QC.

Which infringement scenarios are most at risk?

Answer: The highest-risk scenario is a party making an oral peanut-allergy product using peanut flour lot release that:

1. runs HPLC quantification for Ara h 1/2/6,
2. compares results to reference standard concentrations, and
3. releases/qualifies the lot based on that comparison,
4. then uses the qualified peanut flour in oral formulations.

Contract manufacturing exposure

Because the key steps are QC and suitability identification tied to making, contract manufacturing organizations (CMOs) are likely targets if they run the assay-and-qualify workflow.

Generic entry risk framing

If a generic or follow-on product uses the same peanut flour source but performs QC differently (different analytes, ELISA, LC-MS without matching HPLC framing, different calibration standard, or without the “reference standard comparison suitability identification” step tied to formulation), it can reduce literal infringement exposure. But if their QC documentation and release steps mirror the claim logic, the risk rises sharply.

How strong are the claims on enforceability?

Answer: Strength depends on prior art density and how specifically the patent teaches Ara h 1/2/6 quantification using HPLC with defined reference standards. As provided, the claims are broad enough to capture many QC workflows but specific enough to be distinguishable from more general allergen quantification patents.

What makes these claims enforceable

• explicit requirement of Ara h 1, Ara h 2, and Ara h 6
• explicit requirement of HPLC and comparison to reference standards
• explicit tie between QC suitability decision and downstream oral formulation

What makes them contestable

• functional phrasing around “identifying as suitable” can be challenged as routine/specsmanship unless the patent provides a distinctive framework
• BSA-based quantification and total protein accounting can be vulnerable if not thoroughly enabled or if prior art demonstrates the same calibration logic

What patent-management actions matter most for licensing or litigation?

Answer: Treat US 10,653,773 as a manufacturing-QC gatekeeping patent. The business questions are:

• Does the target product qualify peanut flour lots using HPLC quantification for Ara h 1/2/6 with reference standard comparisons?
• Is the decision step documented as pass/fail against reference concentrations?
• Are BSA/Lowry/peak-area-to-total-protein-area methods used in their QC?
• Is extraction and filtration done as claimed (for dependent claims)?

Key Takeaways

• US 10,653,773 claims a QC-linked method of making an oral peanut-allergy composition where peanut flour is assayed by HPLC for Ara h 1, Ara h 2, Ara h 6, compared to reference standard concentrations, and judged suitable for treatment before formulation.
• Independent claims 1 and 13 are dominated by the QC assay logic; dependent claims narrow to RP-HPLC vs SEC-HPLC, C4/C18 columns, BSA calibration, total protein accounting, Ara h 2/Ara h 6 ratio, and sample prep steps (extraction and filtration), plus capsule/excipient categories.
• The enforcement locus is the manufacturer/CMO performing QC release that links assay comparisons to lot suitability and then to oral formulation.
• Primary validity and narrowing pressure points are novelty/obviousness versus prior peanut-allergen QC analytics, and enablement/written description around calibrants (BSA), quantification approach, and the operational meaning of “reference standard” and “suitable.”

FAQs

1. Can a peanut OIT manufacturer avoid US 10,653,773 by using ELISA instead of HPLC for Ara h 1/2/6?
2. If Ara h concentrations are measured by LC-MS, does that still fall under “HPLC” for infringement purposes?
3. Does using different reference standards or changing assay thresholds eliminate infringement if the same QC logic is followed?
4. How do capsule-filling steps affect risk when only the QC workflow is performed in-house?
5. What is the highest-risk contract manufacturing activity for this patent: extraction, filtration, or chromatographic quantification?

References

1. United States Patent 10,653,773, “Method of making a pharmaceutical composition for treatment of peanut allergy,” claims as provided by user.

Details for Patent 10,653,773

Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Approval Date	Patent No.	Expiredate
Aimmune Therapeutics, Inc.	PALFORZIA	peanut (arachis hypogaea) allergen powder-dnfp	Powder	125696	January 31, 2020		2038-08-23